SCHEMBL22244991

SCHEMBL22244991

COC(=O)C1CC(Oc2c(Br)ccc(-c3cc(=O)c4cccc(Cl)c4o3)c2OC)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP1A1 P04798 5/20 0.36
▸ CYP1B1 Q16678 5/20 0.36
▸ CYP1A2 P05177 3/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CSNK2A2 P19784 3/20 0.34
▸ CSNK2B P67870 3/20 0.34
▸ CSNK2A1 P68400 3/20 0.34
▸ CDK1 P06493 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCNA2 P20248 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22231470 0.92 ALDH1A1 (0.39) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL22231221 0.90 KDM4E (0.39) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL22230959 0.86 HPGD (0.47) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL22245085 0.84 ALDH1A1 (0.42) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL21822978 0.84 HPGD (0.41) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL28618472 0.83 ALDH1A1 (0.37) ALDH1A1HPGDKDM4ECYP3A4MAPT
SCHEMBL22245255 0.82 CYP1A1 (0.51) ALDH1A1HPGDCYP3A4MAPTCYP1A1
SCHEMBL22245265 0.82 CYP1A1 (0.51) ALDH1A1HPGDCYP3A4MAPTCYP1A1
SCHEMBL22232972 0.82 CYP1A1 (0.51) ALDH1A1HPGDCYP3A4MAPTCYP1A1
SCHEMBL22230857 0.82 ALDH1A1 (0.39) ALDH1A1HPGDKDM4ECYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213049-A1 SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2022-07-07 — — US disclosed
CN-113301959-A Substituted chromen-4-ones for the treatment and prevention of hepatitis B virus infection 豪夫迈·罗氏有限公司 2021-08-24 — — CN disclosed
WO-2020148354-A1 SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213049-A1 SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, CYP26B1, CYP7A1 ALDH1A1 420/4885HPGD 1900/4885KDM4E 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback